Publications

Export 11 results:
Sort by: Author Title [ Type (Desc)] Year
Filters: Author is Steg, P Gabriel  [Clear All Filters]
Journal Article
Sinnaeve PR, Steg GP, Fox KA, Van de Werf F, Montalescot G, Granger CB, et al. Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Arch Intern Med. 2009;169(4):402-9. Abstract
Berger PB, Bhatt DL, Fuster V, Steg GP, Fox KA, Shao M, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: Results from the (CHARISMA) trial. Circulation. 2010;121(23):2575-83. Abstract
Berger JS, Bhatt DL, Steg GP, Steinhubl SR, Montalescot G, Shao M, et al. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2011;162(1):98-105.e1. Abstract
Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak K-, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone [CHARISMA] trial). Am J Cardiol. 2009;103(10):1359-63. Abstract
Gurm HS, Gore JM, Anderson FA, Wyman A, Fox KA, Steg GP, et al. Comparison of Acute Coronary Syndrome in Patients Receiving Versus Not Receiving Chronic Dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). The American journal of cardiology. 2011. Abstract
Gurm HS, Gore JM, Anderson FA, Wyman A, Fox KA, Steg GP, et al. Comparison of acute coronary syndrome in patients receiving versus not receiving chronic dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). Am J Cardiol. 2012;109(1):19-25. Abstract
Gurm HS, Gore JM, Anderson FA, Wyman A, Fox KA, Steg GP, et al. Comparison of acute coronary syndrome in patients receiving versus not receiving chronic dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). Am J Cardiol. 2012;109(1):19-25. Abstract
Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 trial. J Am Coll Cardiol. 2009;54(5):468-76. Abstract
Jolly SS, Shenkman H, Brieger D, Fox KA, Yan AT, Eagle KA, et al. Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events. Heart. 2011;97(3):197-202. Abstract
Topol EJ, Bousser M-, Fox KA, Creager MA, Despres J-, Easton DJ, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010;376(9740):517-23. Abstract
Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg GP, Montalescot G, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation. 2009;120(23):2337-44. Abstract